



## A NEW APPROACH TO GENOMIC ANALYSIS

**As part of the financing program set up with Winance in 2019, Genomic Vision announces the drawdown of the fourth tranche and the exercise, by Winance, of the warrants attached to the third tranche**

**Bagneux (France) - Genomic Vision (FR0011799907 – GV)**, a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, announces today the issue of 833,333 new shares, with a nominal value of €0.10 each, at a unit price of €0.52 including premium, through the exercise of the warrants attached to the third tranche issued on February 13, 2020, and 5,000,000 new shares, with a nominal value of €0.10 each, at a unit price of €0.30 including premium, within the framework of the financing contract signed with Winance in accordance with the approval granted by the Company's shareholders at the EGM of March 4, 2019.

As a result of these two transactions, the Company strengthened its cash position and shareholders' equity by €1.9 million, and thus has the necessary resources to develop its activities over the entire financial year. The share capital of Genomic Vision will now consist of 47,130,956 shares. The new shares will be freely tradable and immediately assimilated to the existing ordinary shares listed on the Euronext market in Paris.

The main characteristics of this financing, comprising 4 tranches of shares with equity warrants attached (ABSAs) for a total of €5 million, are described in the Prospectus granted visa number 19-122 by the AMF French stock market authority on March 29, 2019 comprising a *Note d'opération* and a *Document de référence* filed with the AMF under reference number R19-004.

\*\*\*

### **ABOUT GENOMIC VISION**

GENOMIC VISION is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed to high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Based near Paris, in Bagneux, the Company has approximately 30 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext's regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For further information, please visit [www.genomicvision.com](http://www.genomicvision.com)

### **ABOUT WINANCE**

Winance is a global equity investor in SMEs that have a unique competitive advantage and a capacity to deliver short and long-term growth, in order to enable these companies to finance themselves competitively for growth and/or working capital needs.

Website: [www.winance.com](http://www.winance.com)

\*\*\*

## CONTACTS

### Genomic Vision

Dominique Rémy-Renou

CEO

Tel.: +33 1 49 08 07 51

[investisseurs@genomicvision.com](mailto:investisseurs@genomicvision.com)

### Ulysse Communication

#### Press Relations

Bruno Arabian

Tel.: +33 1 42 68 29 70

[barabian@ulyссе-](mailto:barabian@ulyссе-communication.com)

[communication.com](http://communication.com)

### NewCap

#### Investor Relations

#### & Strategic Communications

Tel.: +33 1 44 71 94 94

[gv@newcap.eu](mailto:gv@newcap.eu)



Member of the CAC<sup>®</sup> Mid & Small and CAC<sup>®</sup> All-Tradable indexes

## FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the reference document dated March 29, 2019 filed with the AMF under reference number R19-004, available on the web site of Genomic Vision ([www.genomicvision.com](http://www.genomicvision.com)) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.